SG10201913656TA - Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof - Google Patents

Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof

Info

Publication number
SG10201913656TA
SG10201913656TA SG10201913656TA SG10201913656TA SG10201913656TA SG 10201913656T A SG10201913656T A SG 10201913656TA SG 10201913656T A SG10201913656T A SG 10201913656TA SG 10201913656T A SG10201913656T A SG 10201913656TA SG 10201913656T A SG10201913656T A SG 10201913656TA
Authority
SG
Singapore
Prior art keywords
receptors
chimeric
cells expressing
stimulating
activating
Prior art date
Application number
SG10201913656TA
Inventor
Hong Liu
Pengbo Zhang
Lucas Horan
Yiyang Xu
Binnaz K Staley
Lianxing Liu
Hongruo Yun
Original Assignee
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eureka Therapeutics Inc filed Critical Eureka Therapeutics Inc
Publication of SG10201913656TA publication Critical patent/SG10201913656TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464481—Alpha-feto protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
SG10201913656TA 2017-04-26 2018-04-24 Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof SG10201913656TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490576P 2017-04-26 2017-04-26
US201762490578P 2017-04-26 2017-04-26
US201762490580P 2017-04-26 2017-04-26

Publications (1)

Publication Number Publication Date
SG10201913656TA true SG10201913656TA (en) 2020-03-30

Family

ID=63918704

Family Applications (5)

Application Number Title Priority Date Filing Date
SG10201913656TA SG10201913656TA (en) 2017-04-26 2018-04-24 Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
SG10201913655UA SG10201913655UA (en) 2017-04-26 2018-04-24 Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
SG10201913579WA SG10201913579WA (en) 2017-04-26 2018-04-24 Chimeric antibody/t-cell receptor constructs and uses thereof
SG11201909571S SG11201909571SA (en) 2017-04-26 2018-04-24 Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
SG11201909541W SG11201909541WA (en) 2017-04-26 2018-04-24 Chimeric antibody/t-cell receptor constructs and uses thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
SG10201913655UA SG10201913655UA (en) 2017-04-26 2018-04-24 Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
SG10201913579WA SG10201913579WA (en) 2017-04-26 2018-04-24 Chimeric antibody/t-cell receptor constructs and uses thereof
SG11201909571S SG11201909571SA (en) 2017-04-26 2018-04-24 Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
SG11201909541W SG11201909541WA (en) 2017-04-26 2018-04-24 Chimeric antibody/t-cell receptor constructs and uses thereof

Country Status (12)

Country Link
US (3) US20210093666A1 (en)
EP (2) EP3615046A4 (en)
JP (4) JP2020517287A (en)
KR (2) KR20200014294A (en)
CN (2) CN110741016A (en)
AU (3) AU2018258045B2 (en)
CA (2) CA3059753A1 (en)
IL (2) IL310182A (en)
PH (1) PH12019502411A1 (en)
SG (5) SG10201913656TA (en)
TW (3) TW201902936A (en)
WO (3) WO2018200585A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024757A2 (en) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. compositions and methods for reprogramming tcr using fusion proteins
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
PL3445787T3 (en) 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN110741016A (en) 2017-04-26 2020-01-31 优瑞科生物技术公司 Chimeric antibody/T-cell receptor constructs and uses thereof
JP7414226B2 (en) * 2018-03-30 2024-01-16 エウレカ セラピューティクス インコーポレイテッド Constructs targeting CD22 and their uses
SG11202100838QA (en) * 2018-07-26 2021-02-25 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using target specific fusion proteins
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN111100199B (en) * 2018-12-29 2021-02-12 北京百普赛斯生物科技股份有限公司 Fluorescein labeled protein tetramer and preparation method and application thereof
CN113164626A (en) * 2019-01-14 2021-07-23 南京传奇生物科技有限公司 Chimeric receptor polypeptides and uses thereof
JP7261307B2 (en) * 2019-01-28 2023-04-19 ウーシー バイオロジクス アイルランド リミテッド Novel bispecific CD3/CD20 polypeptide complexes
CN113490689A (en) * 2019-02-01 2021-10-08 佧珐药业有限公司 TCR fusion proteins and cells expressing TCR fusion proteins
KR20220040483A (en) * 2019-07-26 2022-03-30 얀센 바이오테크 인코포레이티드 Proteins comprising kallikrein-associated peptidase 2 antigen binding domains and uses thereof
US20230212319A1 (en) * 2020-03-16 2023-07-06 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
JP2023518293A (en) 2020-03-20 2023-04-28 ライル・イミュノファーマ，インコーポレイテッド A novel recombinant cell surface marker
KR20230006821A (en) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 Modified B cells and methods of use thereof
US11913023B2 (en) 2020-03-31 2024-02-27 Walking Fish Therapeutics, Inc. Modified B cells and methods of use thereof
CN112830973B (en) * 2020-04-08 2022-11-01 苏州克睿基因生物科技有限公司 Chimeric polypeptides and uses thereof
KR20230017786A (en) 2020-04-28 2023-02-06 라이엘 이뮤노파마, 인크. cell culture method
CN115715299A (en) * 2020-05-25 2023-02-24 华夏英泰（北京）生物技术有限公司 Enhanced synthetic T cell receptor antigen receptors
CN116761815A (en) * 2020-07-29 2023-09-15 优瑞科生物技术公司 T cells and chimeric stimulus receptors and uses thereof
WO2022164959A1 (en) 2021-01-27 2022-08-04 Lyell Immunopharma, Inc. Improved immune cell therapy
KR20230150833A (en) 2021-02-25 2023-10-31 라이엘 이뮤노파마, 인크. Cell culture method
CN114957481A (en) * 2021-02-25 2022-08-30 华夏英泰（北京）生物技术有限公司 Dual-target STAR for CD19 and CD22
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
US20230052243A1 (en) 2021-06-02 2023-02-16 Lyell Immunopharma, Inc. Nr4a-deficient cells expressing c-jun and uses thereof
EP4355340A1 (en) 2021-06-16 2024-04-24 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
WO2023070041A1 (en) 2021-10-21 2023-04-27 Lyell Immunopharma, Inc. Enhanced immune cell therapy
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
US20230313138A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
CA3234825A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods of generating cells
WO2023133540A1 (en) 2022-01-07 2023-07-13 Lyell Immunopharma, Inc. Il-12 affinity variants
CN114591443A (en) * 2022-03-07 2022-06-07 皖南医学院第一附属医院（皖南医学院弋矶山医院） Chimeric receptor CSR based on scTv and application thereof
WO2023215738A1 (en) 2022-05-02 2023-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
EP0835306A1 (en) 1995-06-30 1998-04-15 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-mhc complex
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
ES2302726T3 (en) 2000-02-24 2008-08-01 Invitrogen Corporation STIMULATION AND SIMULTANEOUS CONCENTRATION OF CELLS.
CN101289511A (en) 2000-04-11 2008-10-22 杰南技术公司 Multivalent antibodies and uses therefore
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005116072A2 (en) 2004-05-27 2005-12-08 Weidanz Jon A Antibodies as t cell receptor mimics, methods of production and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009508517A (en) 2005-09-22 2009-03-05 コーエン，イルン，アール Immunogenic fragments of T cell receptor constant domains and peptides derived therefrom
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2547248T3 (en) 2006-04-28 2015-10-02 Delenex Therapeutics Ag Antibodies that bind to the extracellular domain of the ALK receptor tyrosine kinase
US20090304657A1 (en) 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2026837A4 (en) 2006-06-01 2010-06-02 Receptor Logic Inc Antibodies as t cell receptor mimics, methods of production and uses thereof
KR101456728B1 (en) 2006-09-08 2014-10-31 메디뮨 엘엘씨 Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008137475A2 (en) 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries
CL2008001334A1 (en) 2007-05-08 2008-09-22 Genentech Inc ANTI-MUC16 ANTIBODY DESIGNED WITH CISTEINE; CONJUGADO THAT UNDERSTANDS IT; METHOD OF PRODUCTION; PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT; AND ITS USE TO TREAT CANCER.
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
UA121093C2 (en) 2008-06-25 2020-04-10 Атенікс Корпорейшн CONSTRUCTION CONTAINING TOXYGEN CODING A PESTICIDAL PROTEIN AND METHOD OF APPLICATION TO KILL SEMI-HARD-WINGED PESTS
TWI580431B (en) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Hig2 and urlc10 epitope peptide and vaccines containing the same
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US20100153133A1 (en) 2008-12-16 2010-06-17 International Business Machines Corporation Generating Never-Event Cohorts from Patient Care Data
WO2010091637A1 (en) 2009-02-10 2010-08-19 Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
AU2010277561A1 (en) 2009-07-30 2012-02-09 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Compositions for generating an antigen specific immune response
CA2778533A1 (en) 2009-10-22 2011-04-28 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PL2552959T3 (en) 2010-03-26 2017-08-31 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
KR20140033029A (en) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CN104379741B (en) 2012-04-23 2021-07-20 基因先端领域株式会社 Anti-human CD69 antibodies and their use for medical purposes
CN103319595B (en) 2012-07-04 2016-12-28 中国药科大学 Anti-human AFP single-chain antibody and the preparation method and application of fused antigen peptide
BR112015000638A2 (en) 2012-07-13 2017-08-08 Univ Pennsylvania isolated nucleic acid sequence, cell, methods for stimulating a cell-mediated immune response to a target cell or tissue population in a mammal, for providing antitumor immunity in a mammal, for treating a mammal having a disease, disorder or condition associated with high expression of a tumor antigen
US20150183877A1 (en) 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
BR112015004522A2 (en) 2012-09-04 2017-11-21 Cellectis multi-chain chimeric antigen receptor and uses of these
EP3597215A1 (en) 2012-10-02 2020-01-22 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN102993305B (en) 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
CN103965362B (en) 2013-02-06 2019-02-01 上海细胞治疗集团有限公司 A kind of chimeric chemokine receptor for making T cell tend to tumor locus
JPWO2014123165A1 (en) 2013-02-06 2017-02-02 旭硝子株式会社 Transparent surface material and display device using the same
RU2680010C2 (en) 2013-02-26 2019-02-14 Мемориал Слоан-Кеттеринг Кэнсер Сентер Compositions and methods of immunotherapy
AU2014236545B2 (en) 2013-03-14 2018-03-01 Agrivida, Inc. Use of dimerization domains for temperature regulation of enzyme activity
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
CN105208866B (en) 2013-03-21 2018-11-23 桑格摩生物治疗股份有限公司 Use engineering zinc finger protein nuclease targeted disruption T cell receptor gene
KR101536668B1 (en) 2013-06-18 2015-07-15 사회복지법인 삼성생명공익재단 Antibodies cross-reactive to Human and Mouse c-Met and Uses thereof
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
DK3027204T3 (en) 2013-07-29 2022-04-19 2Seventy Bio Inc MULTIPLE SIGNAL PROTEINS AND USES THEREOF
WO2015063069A1 (en) 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
CN106414500B (en) 2013-11-07 2020-04-10 纪念斯隆-凯特琳癌症中心 anti-WT 1/HLA bispecific antibodies
CA2934033A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
CN104087592B (en) 2014-05-13 2016-01-27 天津医科大学总医院 AFP 158-166specificity TCR gene and transgenic T cells thereof and in-vitro multiplication method and purposes
US20190030071A1 (en) 2014-11-03 2019-01-31 IMMURES S.r.I. T cell receptors
SG10202007326QA (en) 2014-12-05 2020-08-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
KR20170108946A (en) 2014-12-05 2017-09-27 메모리얼 슬로안-케터링 캔서 센터 Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SI3226897T1 (en) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
US10738116B2 (en) * 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
WO2016154047A2 (en) 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
CA2979732A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
AU2016261356A1 (en) 2015-05-08 2018-01-04 Eureka Therapeutics, Inc. Constructs targeting HPV16-E7 peptide/MHC complexes and uses thereof
EP3297671A4 (en) 2015-05-18 2019-02-06 Eureka Therapeutics, Inc. Anti-ror1 antibodies
BR112017024757A2 (en) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. compositions and methods for reprogramming tcr using fusion proteins
WO2016187216A1 (en) 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
TW201702272A (en) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 T cell receptor-like antibodies specific for a PRAME peptide
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
CN108289950B (en) 2015-06-09 2022-10-21 纪念斯隆凯特琳癌症中心 T-cell receptor-like antibody agents specific for human HLA-presented EBV latent membrane protein 2A peptides
EP3313883B1 (en) 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Novel pd-1 immune modulating agents
US20190382504A1 (en) 2015-06-24 2019-12-19 Eureka Therapeutics, Inc. Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
WO2017015634A2 (en) 2015-07-22 2017-01-26 Eureka Therapeutics, Inc. Constructs targeting psa peptide/mhc complexes and uses thereof
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
JP7017015B2 (en) 2015-10-13 2022-02-08 エウレカ セラピューティクス インコーポレイテッド Antibodies specific to human CD19 and their use
AU2016342041B2 (en) 2015-10-23 2021-12-02 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
CN105331585A (en) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent
SG11201804038VA (en) 2016-01-08 2018-06-28 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
PL3445787T3 (en) 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2020513754A (en) 2016-12-21 2020-05-21 ティーシーアール２ セラピューティクス インク． T cells engineered for cancer treatment
US20190359678A1 (en) 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
CN110741016A (en) 2017-04-26 2020-01-31 优瑞科生物技术公司 Chimeric antibody/T-cell receptor constructs and uses thereof
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins

Also Published As

Publication number Publication date
US11613573B2 (en) 2023-03-28
JP2023093472A (en) 2023-07-04
SG10201913655UA (en) 2020-03-30
US20200115448A1 (en) 2020-04-16
TW201902936A (en) 2019-01-16
JP2024038039A (en) 2024-03-19
TW201902937A (en) 2019-01-16
EP3615046A1 (en) 2020-03-04
IL270136A (en) 2019-12-31
JP2020517295A (en) 2020-06-18
EP3615046A4 (en) 2021-03-03
WO2018200583A1 (en) 2018-11-01
SG11201909571SA (en) 2019-11-28
EP3615567A1 (en) 2020-03-04
US10822413B2 (en) 2020-11-03
CA3059755A1 (en) 2018-11-01
CA3059753A1 (en) 2018-11-01
KR20200012859A (en) 2020-02-05
CN110662547A (en) 2020-01-07
IL270136B1 (en) 2024-02-01
IL310182A (en) 2024-03-01
SG10201913579WA (en) 2020-02-27
AU2018258045B2 (en) 2024-02-29
WO2018200582A1 (en) 2018-11-01
SG11201909541WA (en) 2019-11-28
WO2018200585A1 (en) 2018-11-01
US20210107976A1 (en) 2021-04-15
PH12019502411A1 (en) 2020-09-21
TW201900676A (en) 2019-01-01
RU2019137948A (en) 2021-05-26
EP3615567A4 (en) 2021-06-23
AU2024200970A1 (en) 2024-03-07
US20210101954A1 (en) 2021-04-08
CN110741016A (en) 2020-01-31
KR20200014294A (en) 2020-02-10
RU2019137948A3 (en) 2021-08-26
AU2018258046A1 (en) 2019-12-12
AU2018258045A1 (en) 2019-12-12
JP2020517287A (en) 2020-06-18
US20210093666A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
SG10201913656TA (en) Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
IL273327A (en) Chimeric polypeptides and uses thereof
IL262041A (en) Chimeric receptors and methods of use thereof
IL261941A (en) Chimeric antigen and t cell receptors and methods of use
EP3472208C0 (en) T cell receptors and uses thereof
IL271751A (en) Novel t cell receptors and immune therapy using the same
LT3500593T (en) T cell receptors and immune therapy using the same
IL250828A0 (en) Chimeric receptors and uses thereof in immune therapy
HRP20220131T8 (en) Novel t cell receptors and immune therapy using the same
EP3567049A4 (en) Chimeric antigen receptor and natural killer cells expressing same
ZA201900664B (en) T cell receptors and immune therapy using the same
SG11201909751TA (en) Human alpha fetoprotein-specific t cell receptors and uses thereof
IL289921A (en) Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof
PL2875832T3 (en) Implantable paste and its use
IL269318A (en) Antibodies to human erythroferrone and uses thereof
SG11202004529XA (en) Transformed human cell and use thereof
GB201802896D0 (en) Proprioceptor stimulation material
GB2573931B (en) Electrode material and application thereof
EP3122269A4 (en) Artificial skeletal material and constructs formed therefrom
IL264855B1 (en) T cell receptors and immune therapy using the same
IL267131A (en) Novel t cell receptors and immune therapy using the same
GB201716923D0 (en) Area of use in tidal manipulation
GB201519820D0 (en) Backpack and waterproof pad
ZA201506017B (en) Active body with an active material and a sheath